Our people
Our experienced team of industry experts
Our leadership team
Sentinel Oncology is a drug discovery company passionate about the development of novel therapeutics to treat cancer patients for whom there is currently an unmet medical need. The company’s mission is to discover and develop a pipeline of novel drugs that can treat primary and metastatic brain tumours. The Sentinel Oncology management team has extensive experience in drug research and development and is committed to innovations that improve patients’ lives.
-
Robert G Boyle
Founder & CEO
-
Stuart Travers
Founder & COO
-
David Walker
Director of Chemistry
-
Dr Meriel Major
Associate Director, Chemistry
-
Dr Grahame Mckenzie
Director of Biology
Our Board & Advisors
Sentinel Oncology is supported by an experienced team of advisors, bring invaluable expertise in clinical trials and drug development.
-
Professor Ashok Venkitaraman
Chair of SAB & Board of Directors
-
Professor Anthony Chalmers
Clinical and Brain Cancer Scientific Advisor
-
Professor Duncan Jodrell
Clinical Advisor
-
Andy Baxter
Drug Development Advisor
-
Dr John Dixon
Drug Discovery Advisor & Board of Directors
-
Roy Eady
Regulatory & Scientific Advisor
-
Gavin Simpson
Board of Directors
-
Dan Cowell
Board of Directors